Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This research protocol evaluate the efficacity of intra-articular injections of autologous microfat associated with a preparation of autologous PRP, in symptomatic, resistant to first-line medical treatment, degenerative or post-traumatic cartilage lesions of the knee.
The primary objective of this study is to show the superiority of intra-articular injection of autologous microfat combined with autologous PRP preparation compared to injection of microfat or PRP used alone, on the KOOS score at 6 months.
Osteoarthritis is the most widespread joint disease in the world, and one of the most frequent causes of pain and functional disability in Western countries. The incidence of cartilage lesions is constantly on the rise, due to the ageing of the population and the traumas associated with the development of sporting activities.
Recently, the emergence of biotherapies in orthopaedics has led to the development of intra-articular injections of autologous platelet-rich plasma (PRP). Their use has been widespread since 2010, based on the demonstration that platelet-enriched plasma, a concentrate of growth factors, can stimulate cartilage regeneration in vitro and in vivo in preclinical models (Saito, Schmidt, Qi, Tchetina). In addition, PRP administration methods can be optimized: since it is a liquid preparation (platelet suspension), administering it within an interface tissue limits its diffusion and potentiates its trophic effect on the injured cartilage site. Adipose tissue represents the most relevant tissue of interest, as it is a stem cell-rich support tissue with full therapeutic potential, and is easily accessible. Thus, a sample of autologous "microfat" (adipose tissue containing small fat lobules and stem cells, harvested under local anaesthetic by manual liposuction using specific fine sampling cannulas) co-administered at the level of the synovial capsule, could play the role of fluid trophic matrix to the PRP.
The hypothesis of this project is that the standardized injection of an innovative treatment (microgrease and autologous PRP dose) can defer the need for knee arthroplasty in patients with gonarthrosis resistant to first-line medical treatment. The investigators propose to carry out a clinical study in patients with chondral knee lesions resistant to first-line medical treatment, evaluating the benefit during follow-up of treatment with intra-articular injections of microfat and a standardized preparation of autologous PRP or the combination of the 2.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| autologous microfat (MG) | Experimental | Patient will be hospitalized in outpatient surgery. A blood sample will be collected and a lipoaspiration will be performed under local anesthesia during the same operation by the nurses and the surgeon. Then, biological products will be immediately prepared, and a preparation of autologous MG will be injected intra-articularly by th same surgeon. |
|
| Platelet-rich plasma (PRP) | Experimental | Patient will be hospitalized in outpatient surgery. A blood sample will be collected and a lipoaspiration will be performed under local anesthesia during the same operation by the nurses and the surgeon. Then, biological products will be immediately prepared, and a preparation of autologous PRP will be injected intra-articularly by th same surgeon. |
|
| Microfat autologous-Platelet-rich plasma (MG-PRP) | Experimental | Patient will be hospitalized in outpatient surgery. A blood sample will be collected and a lipoaspiration will be performed for the preparation during the same operation by the nurses and the surgeon. Then, biological products will be immediately prepared, and autologous microfat associated with a preparation of autologous PRP will be injected intra-articularly by th same surgeon. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Intra-articular injection of autologous microfat | Biological | A preparation of autologous microfat (5mL) will be injected intra-articularly. |
|
| Measure | Description | Time Frame |
|---|---|---|
| KOOS score at 6 months | KOOS assesses the short- and long-term consequences of knee injuries, as well as the consequences of primary osteoarthritis. It is percentage from 0 to 100. 0 represents extreme problems and 100 represents no problem. | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Pain at 1 month | Pain will assassed by a visual anatomy scale from 0 (no pain) to 10 (pain as bad as it could possibly be) | 1 month |
| Pain at 3 months | Pain will assassed by a visual anatomy scale from 0 (no pain) to 10 (pain as bad as it could possibly be) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Alexandre ROCHWERGER, Pr | Contact | 04 91 96 63 00 | richardalexandre.rochwerger@ap-hm.fr | |
| Alexandra GIULIANI | Contact | 0491382870 | alexandra.giuliani@ap-hm.fr |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Intra-articular injection of autologous platelet-rich plasma | Biological | A preparation of autologous platelet-rich plasma (5mL) will be injected intra-articularly. |
|
| Intra-articular injection of autologous microfat and platelet-rich plasma | Biological | A preparation of autologous platelet-rich plasma (5mL) and autologous microfat (5mL) will be injected intra-articularly. |
|
| 3 months |
| Pain at 12 months | Pain will assassed by a visual anatomy scale from 0 (no pain) to 10 (pain as bad as it could possibly be) | 12 months |
| KOOS score at 1 month | KOOS assesses the short- and long-term consequences of knee injuries, as well as the consequences of primary osteoarthritis. It is percentage from 0 to 100. 0 represents extreme problems and 100 represents no problem. | 1 month |
| KOOS score at 3 months | KOOS assesses the short- and long-term consequences of knee injuries, as well as the consequences of primary osteoarthritis. It is percentage from 0 to 100. 0 represents extreme problems and 100 represents no problem. | 3 months |
| KOOS score at 12 months | KOOS assesses the short- and long-term consequences of knee injuries, as well as the consequences of primary osteoarthritis. It is percentage from 0 to 100. 0 represents extreme problems and 100 represents no problem. | 12 months |
| Proportion of treatment failures | Patients are defined as treatment failures if, during the follow-up period, they undergo one of the following procedures on the treated knee, in the absence of intercurrent events: new injection (whatever the product injected), arthroscopy, arthroplasty, etc. | 12 months |
| Proportion of arthroplasties not performed in arthroplasty candidates | 12 months |